Japan Tissue Engineering Co

Japan Tissue Engineering Co LT Debt/Equity

Long-Term Debt to Equity Ratio of Japan Tissue Engineering Co (7774.T) as of Nov 20, 2026.

LT Debt/Equity

0.00

Last updated:

Long-Term Debt to Equity Ratio of Japan Tissue Engineering Co is 2023 0.00 . Long-Term Debt to Equity Ratio of Japan Tissue Engineering Co was 2022 0.00 . It decreases by % lower compared to the previous year.

The Japan Tissue Engineering Co LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2021
0.00 JPY
Jan 1, 2022
0.00 JPY
Jan 1, 2023
0.00 JPY
The Japan Tissue Engineering Co LT Debt/Equity history
YEARLT Debt/EquityYoY
0.00-100.00%
0.00-83.65%
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Japan Tissue Engineering Co Stock analysis

What does Japan Tissue Engineering Co do? Japan Tissue Engineering Co., Ltd. generates revenue through three business segments. The Regenerative Medicine Product segment sells autologous cultured epidermis JACE and autologous cultured cartilage JACK to medical institutions. The Regenerative Medicine Outsourcing segment offers CDMO, CRO, consulting, and contract manufacturing services for cell processed products. The Research and Development Support segment sells human cultured tissues developed using the company's advanced culture technology. Medical institutions purchase regenerative medicine products, while pharmaceutical and biotech companies utilize outsourcing services for cell-based therapies. The company's products are sold to healthcare providers and research-focused clients across Japan and potentially internationally. The Regenerative Medicine Product segment focuses on selling JACE and JACK, which are used in medical treatments requiring tissue regeneration. These products are specifically designed for autologous use, meaning they are derived from the patient's own cells. The Outsourcing segment provides specialized services to support the development and manufacturing of cell-based therapies, targeting pharmaceutical and biotech firms. The Research and Development Support segment supplies tissues for research applications, leveraging the company's internal technology to meet client needs in scientific development. JACE and JACK are key products in the Regenerative Medicine Product segment, directly sold to medical institutions for clinical use. The Outsourcing segment serves as a service provider for cell therapy development, offering CDMO and CRO capabilities. The Research and Development Support segment's human cultured tissues are marketed to research organizations seeking advanced cell culture solutions. All segments contribute to the company's revenue by addressing specific needs in regenerative medicine and cell therapy development. Japan Tissue Engineering Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Japan Tissue Engineering Co stock

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Japan Tissue Engineering Co since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Japan Tissue Engineering Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Japan Tissue Engineering Co

All Key Metrics — Japan Tissue Engineering Co